Epigene Therapeutics Inc. announces presentation on NEO2734, an oral dual inhibitor, at the ESMO 2018 Congress

Data demonstrate activity of NEO2734, with superior effects to those of standard BET inhibitors, in colon and prostate cancer animal models

MONTREAL, Oct. 16, 2018 /CNW Telbec/ - Epigene Therapeutics Inc. announces that data on NEO2734, its investigational, first-in-class, dual inhibitor of both the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins and the Cyclic AMP response element binding protein (CREB)-binding protein (CBP) and E1A interacting protein of 300 kDa (EP300 or P300) will be presented at the upcoming European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich, Germany from October 19^th to the 23^rd, 2018. The data being presented at ESMO 2018 will include a poster presentation on NEO2734 activity in the VCaP prostate cancer model and the MC38 colon cancer model.

"Epigenetic changes are a major force in the genetic dysregulation that underlies the development and progression of human cancer", stated Professor Razelle Kurzrock, Chief, Division of Hematology and Oncology, University of California, San Diego, Senior Deputy Center Director, Clinical Science, Director, Center for Personalized Cancer Therapy University of California, San Diego - Moores Cancer Center, San Diego, CA and member of the Epigene Therapeutics Scientific Advisory Board (SAB). "We have made limited progress in deriving meaningful clinical benefit from the use of epigentic modifying agents. While the traditional BET inhibitors have shown consistent clinical promise in a spectrum of both hematologic maligancies and solid tumors, none have been granted regulatory approval. Developmental therapeutics efforts are now focused primarily on finding the right partner agents for BET inhibitors in order to increase their activity in patients. NEO2734 mediates multiple epigenetic modifer effects in a single agent and thus represents a unique, very exciting novel therapeutic approach"

"NEO2734 simultaneously inhibits two very well established classes of major epigenetic targets in patients with cancer", said Dr. Elena Garralda, Principal Investigator and Executive Director of the Early Drug Development Unit Vall d' Hebron Institute of Oncology, Barcelona, who is also a member of the Epigene Therapeutics SAB. "Intensive efforts are ongoing to define the role of BET inhibitors as anti-cancer therapies while the CBP-EP300/P300 family of transcriptional coactivators are emerging as independent important therapeutic targets in oncology. NEO2734 offers us the unique opportunity to inhibit chromatin readers and writers with a single agent. The pre-clinical data being presented at ESMO on its activity in both colon and prostate cancers are particularly important in this context as our knowledge on the connections between specific epigenetic changes, deficiencies in DNA repair mechanisms, and therapeutic targets rapidly evolve."

"Synergistic activity against two independent important targets in cancer delivered by a single agent is a very rare phenomenon," said Francis Giles, Epigene Therapeutics' Chief Medical Officer & Chief Operating Officer. "NEO2734 is unique in delivering that activity against both the BET and CBP-P300 targets and thus provides novel opportunities to both optimize the activity of the BET inhibitors and utilize CBP-P300 as a target. On-going IND-enabling work combined with multiple collaborations between Epigene Therapeutics and global academic leaders are rapidly defining the path to clinic for NEO2734"

Poster details:

"NEO2734: A novel potent oral dual BET and P300/CBP inhibitor"
(Abstract #429P, poster display session Hall A3 ? Developmental Therapeutics)
 ? Monday, 22 October 2018 from 12:45 p.m. CEST to 1:45 p.m. CEST

Full session details and data presentation listings for ESMO 2018 can be found at: https://cslide.ctimeetingtech.com/esmo2018/attendee/.

About Epigene Therapeutics Inc.

Epigene Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of epigenetic modifying agents for the treatment of patients with cancer.

For more information please click here

SOURCE NEOMED Therapeutics 1